tirzepatide cvs caremark will cover Lilly's weight loss drug Zepbound again after patient backlash CVS Caremark Expands GLP-1 Formulary

Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight)

Astrup A, Bgel S

Important safety considerations include a boxed warning for thyroid C-cell tumors (contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2), and risks of pancreatitis, gallbladder disease, acute kidney injury from dehydration, and hypoglycemia when used with insulin or sulfonylureas

Beyond current indications, Alberta Blue Cross identifies potential future expanded uses including: Metabolic dysfunction-associated steatohepatitis (MASH) [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php] Obstructive sleep apnea (OSA) [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php] The insurer characterizes the developing GLP-1 pipeline as robust, with treatments described as more effective, broader in use, and longer between doses [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]

Actual results may vary

The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the healthcare system, the department said in its news release